

# Stephen L Lessnick

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2224751/publications.pdf>

Version: 2024-02-01

52  
papers

4,594  
citations

147801

31  
h-index

161849

54  
g-index

60  
all docs

60  
docs citations

60  
times ranked

4682  
citing authors

#	ARTICLE	IF	CITATIONS
1	A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS family transcription factor, ERG. <i>Nature Genetics</i> , 1994, 6, 146-151.	21.4	693
2	Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. <i>Lancet Oncology</i> , The, 2016, 17, 1396-1408.	10.7	356
3	Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. <i>European Journal of Cancer</i> , 2019, 109, 36-50.	2.8	354
4	Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. <i>Cancer Cell</i> , 2006, 9, 405-416.	16.8	307
5	Microsatellites as EWS/FLI response elements in Ewing's sarcoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 10149-10154.	7.1	246
6	The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts. <i>Cancer Cell</i> , 2002, 1, 393-401.	16.8	239
7	EWS FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma. <i>Nature</i> , 2018, 555, 387-391.	27.8	222
8	Promiscuous partnerships in Ewing's sarcoma. <i>Cancer Genetics</i> , 2011, 204, 351-365.	0.4	213
9	NROB1 Is Required for the Oncogenic Phenotype Mediated by EWS/FLI in Ewing's Sarcoma. <i>Molecular Cancer Research</i> , 2006, 4, 851-859.	3.4	182
10	Molecular Pathogenesis of Ewing Sarcoma: New Therapeutic and Transcriptional Targets. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2012, 7, 145-159.	22.4	160
11	Reversible LSD1 Inhibition Interferes with Global EWS/ETS Transcriptional Activity and Impedes Ewing Sarcoma Tumor Growth. <i>Clinical Cancer Research</i> , 2014, 20, 4584-4597.	7.0	138
12	A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature. <i>Cell Cycle</i> , 2008, 7, 250-256.	2.6	136
13	Signature-Based Small Molecule Screening Identifies Cytosine Arabinoside as an EWS/FLI Modulator in Ewing Sarcoma. <i>PLoS Medicine</i> , 2007, 4, e122.	8.4	129
14	Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. <i>British Journal of Cancer</i> , 2018, 119, 615-621.	6.4	83
15	The EWS/FLI Oncogene Drives Changes in Cellular Morphology, Adhesion, and Migration in Ewing Sarcoma. <i>Genes and Cancer</i> , 2012, 3, 102-116.	1.9	82
16	Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing sarcoma: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1771-1779.	1.5	81
17	Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting. <i>Oncotarget</i> , 2016, 7, 17616-17630.	1.8	62
18	Role for the EWS domain of EWS/FLI in binding GGAA-microsatellites required for Ewing sarcoma anchorage independent growth. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 9870-9875.	7.1	57

#	ARTICLE	IF	CITATIONS
19	Expression of EWS-ETS Fusions in NIH3T3 Cells Reveals Significant Differences to Ewing's Sarcoma. <i>Cell Cycle</i> , 2006, 5, 2753-2759.	2.6	56
20	Emergent Properties of EWS/FLI Regulation via GGAA Microsatellites in Ewing's Sarcoma. <i>Genes and Cancer</i> , 2010, 1, 177-187.	1.9	56
21	Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor. <i>Clinical Cancer Research</i> , 2016, 22, 4105-4118.	7.0	56
22	Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1902-1916.	4.1	48
23	Molecular dissection of the mechanism by which EWS/FLI expression compromises actin cytoskeletal integrity and cell adhesion in Ewing sarcoma. <i>Molecular Biology of the Cell</i> , 2014, 25, 2695-2709.	2.1	47
24	ZEB2 Represses the Epithelial Phenotype and Facilitates Metastasis in Ewing Sarcoma. <i>Genes and Cancer</i> , 2013, 4, 486-500.	1.9	46
25	Recent advances in targeted therapy for Ewing sarcoma. <i>F1000Research</i> , 2016, 5, 2077.	1.6	45
26	Microsatellites are EWS/FLI response elements: Genomic "junk" is EWS/FLI's treasure. <i>Cell Cycle</i> , 2008, 7, 3127-3132.	2.6	40
27	Identification of two types of GGAA-microsatellites and their roles in EWS/FLI binding and gene regulation in Ewing sarcoma. <i>PLoS ONE</i> , 2017, 12, e0186275.	2.5	40
28	EWS/FLI is a Master Regulator of Metabolic Reprogramming in Ewing Sarcoma. <i>Molecular Cancer Research</i> , 2017, 15, 1517-1530.	3.4	39
29	Clinical and Biochemical Function of Polymorphic NROB1 GGAA-Microsatellites in Ewing Sarcoma: A Report from the Children's Oncology Group. <i>PLoS ONE</i> , 2014, 9, e104378.	2.5	38
30	EWS/FLI utilizes NKX2-2 to repress mesenchymal features of Ewing sarcoma. <i>Genes and Cancer</i> , 2015, 6, 129-143.	1.9	38
31	EWS/FLI-responsive GGAA microsatellites exhibit polymorphic differences between European and African populations. <i>Cancer Genetics</i> , 2012, 205, 304-312.	0.4	34
32	Trabectedin Inhibits EWS-FLI1 and Evicts SWI/SNF from Chromatin in a Schedule-dependent Manner. <i>Clinical Cancer Research</i> , 2019, 25, 3417-3429.	7.0	32
33	Identifying States of Collateral Sensitivity during the Evolution of Therapeutic Resistance in Ewing's Sarcoma. <i>IScience</i> , 2020, 23, 101293.	4.1	24
34	Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group. <i>Clinical Cancer Research</i> , 2016, 22, 3643-3650.	7.0	23
35	EWS and RE1-Silencing Transcription Factor Inhibit Neuronal Phenotype Development and Oncogenic Transformation in Ewing Sarcoma. <i>Genes and Cancer</i> , 2013, 4, 213-223.	1.9	21
36	Transcriptomic analysis functionally maps the intrinsically disordered domain of EWS/FLI and reveals novel transcriptional dependencies for oncogenesis. <i>Genes and Cancer</i> , 2019, 10, 21-38.	1.9	19

#	ARTICLE	IF	CITATIONS
37	Targeting Glutathione S-transferase M4 in Ewing sarcoma. <i>Frontiers in Pediatrics</i> , 2014, 2, 83.	1.9	18
38	Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis. <i>Journal of Visualized Experiments</i> , 2020, , .	0.3	18
39	Chromatin profiling reveals relocalization of lysine-specific demethylase 1 by an oncogenic fusion protein. <i>Epigenetics</i> , 2021, 16, 405-424.	2.7	18
40	The FLI portion of EWS/FLI contributes a transcriptional regulatory function that is distinct and separable from its DNA-binding function in Ewing sarcoma. <i>Oncogene</i> , 2021, 40, 4759-4769.	5.9	14
41	Survey of Paediatric Oncologists and Pathologists regarding Their Views and Experiences with Variant Translocations in Ewing and Ewing-Like Sarcoma: A Report of the Children's Oncology Group. <i>Sarcoma</i> , 2020, 2020, 1-9.	1.3	12
42	C/EBP $\beta$ -1 promotes transformation and chemoresistance in Ewing sarcoma cells. <i>Oncotarget</i> , 2017, 8, 26013-26026.	1.8	12
43	Ewing sarcoma resistance to SP-2509 is not mediated through KDM1A/LSD1 mutation. <i>Oncotarget</i> , 2018, 9, 36413-36429.	1.8	10
44	Identification of a Novel <i>FUS/ETV4</i> Fusion and Comparative Analysis with Other Ewing Sarcoma Fusion Proteins. <i>Molecular Cancer Research</i> , 2021, 19, 1795-1801.	3.4	9
45	Network potential identifies therapeutic miRNA cocktails in Ewing sarcoma. <i>PLoS Computational Biology</i> , 2021, 17, e1008755.	3.2	9
46	Protein phosphatase 1 regulatory subunit 1A regulates cell cycle progression in Ewing sarcoma. <i>Oncotarget</i> , 2020, 11, 1691-1704.	1.8	6
47	Patterns of Translocation Testing in Patients Enrolling in a Cooperative Group Trial for Newly Diagnosed Metastatic Ewing Sarcoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 1564-1568.	2.5	4
48	Response to imaging guidelines for children with Ewing sarcoma and osteosarcoma: A report from the Children's Oncology Group Bone Tumor Committee. <i>Pediatric Blood and Cancer</i> , 2008, 51, 839-840.	1.5	3
49	Increased risk for other cancers in individuals with Ewing sarcoma and their relatives. <i>Cancer Medicine</i> , 2019, 8, 7924-7930.	2.8	3
50	Mitochondrial Dysfunction Is a Driver of SP-2509 Drug Resistance in Ewing Sarcoma. <i>Molecular Cancer Research</i> , 2022, 20, 1035-1046.	3.4	3
51	Investigating the role of LSD2 as an epigenetic regulator in Ewing sarcoma. <i>Oncotarget</i> , 2019, 10, 3865-3878.	1.8	2
52	Phase 1 expansion trial of the LSD1 inhibitor seclidemstat (SP-2577) with and without topotecan and cyclophosphamide (TC) in patients (pts) with relapsed or refractory Ewing sarcoma (ES) and select sarcomas.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS11577-TPS11577.	1.6	1